Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting
October 27 2021 - 7:30AM
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company
dedicated to the development of innovative therapeutics for
neurotology, today announced multiple presentations at the upcoming
Neuroscience 2021 meeting, which is the annual meeting of the
Society for Neuroscience (SfN). This meeting will be held virtually
November 8-11, 2021 with Preview Days taking place November 3-7
during which registered attendees can preview pre-recorded
presentations. Otonomy’s presentations include the previously
disclosed positive top-line clinical results for OTO-313 in
tinnitus and OTO-413 in hearing loss, and multiple presentations
related to Otonomy’s preclinical programs.
“We are pleased to have the opportunity to review the positive
clinical results for OTO-313 and OTO-413 for the broader
neuroscience research community during this prestigious
conference,” said Alan C. Foster, Ph.D., chief scientific officer
of Otonomy. “Our multiple presentations highlight the breadth of
our pipeline and provide supportive data for our preclinical
programs including OTO-825, a gene therapy for congenital hearing
loss, and OTO-510, an otoprotectant for cisplatin-induced hearing
loss.”
The following presentations related to Otonomy’s clinical
programs will be held during interactive poster sessions occurring
from 3:15 to 4:15 p.m. EST on November 8.
- “Initial clinical evaluation of OTO-313 given as a single
intratympanic injection in patients with moderate to severe,
persistent tinnitus” by Anderson et al.
- “A first-in-human study of OTO-413, an intratympanic
sustained-exposure formulation of BDNF, for the treatment of
hearing loss” presented by Victoria Sanchez, Au.D., Ph.D.,
Assistant Professor of University of South Florida and principal
investigator on the study.
All other Otonomy presentations are during interactive poster
sessions occurring from 3:30 to 4:30 p.m. EST on November 10.
- “AAV-mediated gene therapy with OTO-825 rescues hearing loss
and cochlear degeneration in two mouse models of GJB2 congenital
hearing loss” a joint presentation from Otonomy and Applied
Genetics Technology Corporation (AGTC) by Uribe et al.
- “Local delivery of BDNF (OTO-413) and a selective TrkB agonist
(M3) restores hearing function in models of cochlear synaptopathy”
by Fernandez et al.
- “Identification and characterization of OTO-510 as a novel
approach to the prevention of cisplatin-induced hearing loss” by
Mathur et al.
- “Novel fab fragments derived from Trk-selective agonist
monoclonal antibodies are potent and selective antagonists of the
TrkB and TrkC receptors” by Siegel et al.
About OtonomyOtonomy is a biopharmaceutical
company dedicated to the development of innovative therapeutics for
neurotology. The company pioneered the application of drug delivery
technology to the ear in order to develop products that achieve
sustained drug exposure from a single local administration. This
approach is covered by a broad patent estate and is being utilized
to develop a pipeline of products addressing important unmet
medical needs including Ménière’s disease, hearing loss, and
tinnitus. For additional information please visit
www.otonomy.com.
Contacts:
Media Inquiries:Spectrum ScienceChloé-Anne RamseyVice
President404.865.3601cramsey@spectrumscience.com
Investor Inquiries:Westwicke ICRRobert H. UhlManaging
Director858.356.5932robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Aug 2023 to Aug 2024